<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644538</url>
  </required_header>
  <id_info>
    <org_study_id>APACE</org_study_id>
    <nct_id>NCT02644538</nct_id>
  </id_info>
  <brief_title>Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides</brief_title>
  <official_title>A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>People's Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Xinjiang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether PegIFN alfa-2a add on can improve CHB patients HBsAg clearance
      at the end of 48 weeks treatment. The CHB patients who received nucleot(s)ides anti-virus
      treatment and reached HBV DNA&lt;1000 copies/ml and HBsAg&lt;3000 IU/ml, were randomly assigned
      into two groups: One group continue the nucleot(s)ides treatment for 72 weeks, the other add
      on PegIFN alfa-2a on the basis of the original treatment for 48 weeks, and follow up for 24
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      nucleot(s)ides is a potent inhibitor of hepatitis B viral(HBV) replication, but long-term
      therapy may be required, and it is difficult for CHB patients to achieve HBsAg clearance by
      using nucleot(s)ides. Therefore, it is need take long-term therapy if chronic hepatitis B
      (CHB) choose to use nucleot(s)ides, and in another way, nucleot(s)ides resistance is an
      important clinical risk. More and more young patients want to stop treating, and
      discontinuation of nucleot(s)ides is a feasible strategy to reduce resistance. However, it is
      really easy to relapse if patients did not arrive HBsAg clearance. PegIFN alfa-2a can clear
      HBV by direct anti-viral and immune regulation mechanisms including enhancing natural killer
      cell response, increased cluster of differentiation 8(CD8 +) T lymphocytes and other
      mechanisms to restore and enhance the immune response in patients with CHB; and what's more,
      patients are safety after discontinuing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who achieve HBsAg clearance</measure>
    <time_frame>treat for 48 weeks</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a add on treatment can improve the HBsAg clearance in CHB patients at the end of the treatment (48 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBsAg seroconversion</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a add on treatment can improve the HBsAg seroconversion in CHB patients at the end of the treatment (48 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBeAg clearance and seroconversion</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a add on treatment can improve HBeAg clearance and seroconversion at the end of the treatment (48 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBsAg changes from Baseline</measure>
    <time_frame>12,24 and 48 weeks</time_frame>
    <description>Pegasys 24 weeks Group:12,24 weeks and Pegasys 48 weeks Group:12,24,48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who achieve HBV DNA&lt;1000 copies/ml</measure>
    <time_frame>12,24 and 48 weeks</time_frame>
    <description>To investigate whether Peg-IFN alfa-2a add on treatment can improve HBV DNA&lt;1000 copies/ml</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>nucleot(s)ides treated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PegIFN alfa-2a + nucleot(s)ides treated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegIFN alfa-2a</intervention_name>
    <description>chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA &lt;1000copies/ml, and HBsAg&lt;3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks</description>
    <arm_group_label>PegIFN alfa-2a + nucleot(s)ides treated</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects,18-65 years

          2. positive for hepatitis B surface antigen (HBsAg) and negative for antibodies to HBsAg
             (anti-HBs antibodies) for at least 6 months before NAs treated

          3. nucleot(s)ides monotherapy (including lamivudine, adefovir, entecavir, tenofovir) and
             achieved HBV DNA&lt;1000 copies/mL with HBsAg &lt;3000 IU/mL, positive or negative for
             HBeAg, and negative for anti-HBs antibodies

          4. Subjects with no contra-indications to Peginterferon alfa therapy as detailed in the
             label (Hypersensitivity to the active substance, to alpha interferon, or to any of the
             excipients; Autoimmune hepatitis; Severe hepatic dysfunction or decompensated
             cirrhosis of the liver; A history of severe pre-existing cardiac disease, including
             unstable or uncontrolled cardiac disease in the previous six months)

          5. Subjects who are not co-infected with Hepatitis A Virus, Hepatitis C Virus or HIV

          6. Female subjects not pregnant or breast feeding when Peginterferon alfa treatment
             commenced, and aware of the requirement to use an effective method of contraception
             during therapy

          7. Written informed consent signed.

        Exclusion Criteria:

          1. positive for Hepatitis A Virus Ab, HCV-RNA or positive for Hepatitis C Virus Ab, HDV
             Ab, HEV Ab or positive for HIV Ab in screening period

          2. Hepatocellular carcinoma(HCC) or alpha feto protein(AFP) levels more than 100 ng/ml
             and Hepatic malignant potential of Imaging examination or AFP levels more than 100
             ng/ml for 3 months

          3. Compensated or Decompensated liver cirrhosis: with history of cirrhosis before
             nucleot(s)ides treatment or Child-Pugh score ≥ 5 or Complications of liver cirrhosis
             such as ascites, hepatic encephalopathy, esophageal gastric varices bleeding

          4. Autoimmune disease including Autoimmune hepatitis and Psoriasis and so on

          5. Pregnant women and lactating women or patients with pregnancy plans and not willing to
             use contraception during the study period

          6. A history of immunoregulation drug therapy within one year before entry including IFN
             and so on

          7. Have a history of alcohol abuse

          8. With severe psychiatric condition or nervous disease such as epilepsy, depression,
             mania, epilepsy, schizophrenia and so on

          9. A neutrophil count of less than 1500 per cubic millimeter or a platelet count of less
             than 90,000 per cubic millimeter

         10. Severe organ dysfunction

         11. With other malignant tumors(exclude the cured ones)

         12. Uncontrolled diabetes, hypertension or thyroid disease

         13. A serum creatinine level that was more than 1.5 times the upper limit of the normal
             range

         14. Hypersensitivity to interferon(IFN) or its active substance, and ineligible to IFN

         15. Participate in other clinical studies at the same time

         16. Patients unsuitable for the research -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Review. Erratum in: N Engl J Med. 2004 Sep 16;351(12):351.</citation>
    <PMID>15014185</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009 Nov 5;27(47):6550-7. doi: 10.1016/j.vaccine.2009.08.048. Epub 2009 Sep 1.</citation>
    <PMID>19729084</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl). 2009 Jan 5;122(1):3-4.</citation>
    <PMID>19187608</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20. Erratum in: J Hepatol. 2013 Jan;58(1):201. Janssen, Harry [corrected to Janssen, Harry L A].</citation>
    <PMID>22436845</PMID>
  </results_reference>
  <results_reference>
    <citation>Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol. 2013 Feb;58(2):225-33. doi: 10.1016/j.jhep.2012.09.029. Epub 2012 Oct 6.</citation>
    <PMID>23046671</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen J, Wang Y, Wu XJ, Li J, Hou FQ, Wang GQ. Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World J Gastroenterol. 2010 Dec 28;16(48):6145-50.</citation>
    <PMID>21182232</PMID>
  </results_reference>
  <results_reference>
    <citation>Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, Rothe V, Popescu M, Brunetto MR. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013 Mar;7(1):88-97. doi: 10.1007/s12072-012-9343-x. Epub 2012 Mar 23.</citation>
    <PMID>23518903</PMID>
  </results_reference>
  <results_reference>
    <citation>Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013 Jun;7(2):429-36. doi: 10.1007/s12072-011-9280-0. Epub 2011 Jun 24.</citation>
    <PMID>21701902</PMID>
  </results_reference>
  <results_reference>
    <citation>Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014 Oct;61(4):777-84. doi: 10.1016/j.jhep.2014.05.044. Epub 2014 Jun 7.</citation>
    <PMID>24915612</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2016</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Peng Hu</investigator_full_name>
    <investigator_title>Director of Department of infection disease</investigator_title>
  </responsible_party>
  <keyword>HBsAg clearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>still undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

